Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif.
Optimization of the biological activity of a new class of non-peptidyl, pyridazinone derived human melanocortin subtype-4 receptor agonists is disclosed.
Ujjainwalla
Feroze
F
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. f_ujjainwalla@merck.com
Warner
Daniel
D
Snedden
Christine
C
Grisson
Ricky D
RD
Walsh
Thomas F
TF
Wyvratt
Matthew J
MJ
Kalyani
Rubana N
RN
Macneil
Tanya
T
Tang
Rui
R
Weinberg
David H
DH
Van der Ploeg
Lex
L
Goulet
Mark T
MT
D015195:Drug Design; D006801:Humans; D020128:Inhibitory Concentration 50; D015394:Molecular Structure; D011724:Pyridazines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D044105:Receptor, Melanocortin, Type 4 / Q000819:agonists* / Q000378:metabolism; D013329:Structure-Activity Relationship
C470072:MC4R protein, human; D011724:Pyridazines; D044105:Receptor, Melanocortin, Type 4